Evidence map›Paper›PMID 29541273›Full record

ArticleThe open virology journal2018

Protection Efficacy of C5A Against Vaginal and Rectal HIV Challenges in Humanized Mice.

Philippe A Gallay, Udayan Chatterji, Aaron Kirchhoff, Angel Gandarilla, Richard B Pyles, Marc M Baum, John A Moss

Open access · diamondAbstract read
In one paragraph

Article in The open virology journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Philippe A GallayDepartment of Immunology & Microbiology, The Scripps Research Institute; La Jolla, California 92037, USA.
Udayan ChatterjiDepartment of Immunology & Microbiology, The Scripps Research Institute; La Jolla, California 92037, USA.
Aaron KirchhoffDepartment of Immunology & Microbiology, The Scripps Research Institute; La Jolla, California 92037, USA.
Angel GandarillaDepartment of Immunology & Microbiology, The Scripps Research Institute; La Jolla, California 92037, USA.
Richard B PylesDepartment of Pediatrics, University of Texas Medical Branch; Galveston, Texas 77555-0436, USA.
Marc M BaumDepartment of Chemistry, Oak Crest Institute of Science; Monrovia, California 91107. USA.
John A MossDepartment of Chemistry, Oak Crest Institute of Science; Monrovia, California 91107. USA.
Scripps Research Institute · USOak Crest Institute of Science · USThe University of Texas Medical Branch at Galveston · US

Funding

Analyses of the Antiviral and Antifibrotic Mechanisms of Action of NS5A and Cyclophilin InhibitorsR01AI125365 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI GALLAY, PHILIPPE ANDRE · 2017 to 2021
$2.4M
C5a as an Anti-HIV Microbicidal CandidateR01AI087470 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI GALLAY, PHILIPPE ANDRE · 2010 to 2014
$2.3M
Inhibitors of HIV-Dendritic Cell Interactions as MicrobicidesR33AI076005 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI GALLAY, PHILIPPE ANDRE · 2009 to 2011
$1.6M
Anti-HIV Microbicidal PeptidesR33AI079782 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI GALLAY, PHILIPPE ANDRE · 2011 to 2013
$1.6M
Anti-HIV Microbicidal PeptidesR21AI079782 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI GALLAY, PHILIPPE ANDRE · 2009 to 2010
$903k
Inhibitors of HIV-Dendritic Cell Interactions as MicrobicidesR21AI076005 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI GALLAY, PHILIPPE ANDRE · 2007 to 2008
$504k
NIAID NIH HHS R01 AI087470NIAID NIH HHS R01 AI125365NIAID NIH HHS R21 AI076005NIAID NIH HHS R21 AI079782NIAID NIH HHS R33 AI076005NIAID NIH HHS R33 AI079782
6 · The paper itself

Abstract

introductionIn the absence of a vaccine, there is an urgent need for the identification of effective agents that prevent HIV transmission in uninfected individuals. Non-vaccine Biomedical Prevention (nBP) methods, such as topical or systemic pre-exposure prophylaxis (PrEP), are promising strategies to slow down the spread of AIDS.

methodsIn this study, we investigated the microbicidal efficacy of the viral membrane-disrupting amphipathic SWLRDIWDWICEVLSDFK peptide called C5A. We chose the bone marrow/liver/thymus (BLT) humanized mouse model as vaginal and rectal HIV transmission models.

resultsWe found that the topical administration of C5A offers complete protection against vaginal and rectal HIV challenges in humanized mice. After demonstrating that C5A blocks genital HIV transmission in humanized mice, we examined the molecular requirements for its microbicidal property. We found that the removal of four amino acids on either end of C5A does not diminish its microbicidal efficacy. However, the removal of four amino acids at both the ends, abolishes its capacity to prevent vaginal or rectal HIV transmission, suggesting that the length of the peptide is a critical parameter for the microbicidal activity of C5A. Moreover, we demonstrated that the amphipathicity of the helical peptide as well as its hydrophobic surface represents key factors for the microbicidal activity of C5A in humanized mice.

conclusionWith its noncellular cytotoxic activity, its property of neutralizing both HSV and HIV, and its unique mechanism of action that disrupts the stability of the viral membrane, C5A represents an attractive multipurpose microbicidal candidate to be combined with other anti-HIV agents including antiretrovirals.

Indexed as

Bone marrow/Liver/Thymus MiceC5AHIV transmissionMicrobicideRectal challengeVaginal challenge

Identifiers

PMID29541273
PMCPMC5842390
OpenAlexW2789084689

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.